Nabsys Expands OhmX Platform for AML and MDS Research
San Diego, California – May 17, 2026 Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM)...
hematologic malignancies
Advertisement
Orca Bio Secures FDA RMAT Status for Orca-Q Therapy
MENLO PARK, Calif., April 28, 2026 Orca Bio has announced that the U.S. Food and Drug Administration (FDA) has...
Tempus AI, Predicta Expand Genomics Test for Blood Cancer
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
AI-NGS Test Detects AML, MDS Relapse Post-Transplant
BRISBANE, Calif., Feb. 12, 2026 — CareDx announced pivotal clinical validation results for AlloHeme, the first AI-powered, next-generation sequencing...
BeOne Medicines’ Sonrotoclax Gets FDA Breakthrough Status
October 13, 2025 | USA – BeOne Medicines, a clinical-stage biopharmaceutical company, announced that its investigational drug Sonrotoclax has...
Advertisements
Tezspire Wins CHMP Backing for Chronic Rhinosinusitis in EU
September 22, 2025 – Brussels, Belgium – AstraZeneca and Amgen announced that the European Medicines Agency’s (EMA) Committee for...
Jaypirca Gains Approval as First Non-Covalent BTK Inhibitor for CLL/SLL
INDIANAPOLIS, September 8, 2025 — Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, has demonstrated a...
Advertisement
